Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093)

Cancer Chemotherapy and Pharmacology

Volumn 55, Issue 1, 2005, Pages 72-78

  Kuppens, I E L M ^a   Bosch, T M ^a   Van Maanen, M J ^a   Rosing, H ^a   Fitzpatrick, A ^b   Beijnen, J H ^a,c   Schellens, J H M ^a,c  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ELAN PHARMACEUTICALS   (United States)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Bioavailability; Docetaxel; OC144 093; Oral administration; P glycoprotein; Pharmacogenetics; Pharmacokinetics

Indexed keywords

DEXAMETHASONE; DOCETAXEL; GLYCOPROTEIN P INHIBITOR; GRANISETRON; MULTIDRUG RESISTANCE PROTEIN 1; ONT 093; UNCLASSIFIED DRUG;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW TOXICITY; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; GENETIC POLYMORPHISM; HUMAN; MALAISE; MALE; NAUSEA; NEUROLOGIC DISEASE; NEUROPATHY; NEUTROPENIA; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SENSORY DYSFUNCTION; SOLID TUMOR; STOMATITIS; VOMITING;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL AVAILABILITY; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; TAXOIDS;

EID: 11244321887     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0864-4     Document Type: Article

References (27)

1. Bardelmeijer HA, Ouwehand M, Buckle T, Huisman MT, Schellens JHM, Beijnen JH, van Tellingen O (2002) Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res 62:6158
2. Boom R, Sol CJA, Salimans MMM, Jansen CL, Wertheim-van Dillen PME, Noordaa J (1990) Rapid and simple method for purification of nucleic acids. J Clin Microbiol 28:495
3. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbau M, Brinkmann U, Roots I (2001) Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69:169
4. Climent MA, Ruiz A, Llombart-Cussac A, Fernandez-Martos C, Poveda A, Dorta J, Guillem V (1999) Weekly docetaxel in patients with advanced malignancies. Toxicity profile and activity results. Proc Am Soc Clin Oncol 18:119a
5. DeMario MD, Ratain MJ (1998) Oral chemotherapy: rationale and future directions. J Clin Oncol 16:2557
6. Drescher S, Schaeffeler E, Hitzl M, Hofmann U, Schwab M, Brinkmann U, Eichelbaum M, Fromm MF (2002) MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 53:526
7. Frasci G, Comella P, D'Aiuto G, Thomas R, Capnoso I, Elmo M, Botti G, Cortino GR, Lapental L, DeRosa V, Vallone P, Petrillo A, Comella G (2000) Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: a parallel dose-finding study. Southern Italy Cooperative Oncology Group (SICOG). Ann Oncol 11:367
8. Gerloff T, Schaefer M, Johne A, Oselin K, Meisel C, Cascorbi I, Roots I (2002) MDR genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br J Clin Pharmacol 54:610
9. Goh B-C, Lee S-C, Wang L-Z, Fan L, Guo J-Y, Lamba J, Schuetz E, Lim R, Lim H-L, Ong A-B, Lee H-S (2002) Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 20:3683
10. Division of Cancer Treatment (1998) Guidelines for reporting of adverse drug reactions. National Cancer Institute, Bethesda, MD
11. Guns ES, Bullock PL, Reimer ML, Dixon R, Bally M, Mayer LD (2001) Assessment of the involvement of CYP3A in the vitro metabolism of a new modulator of MDR in cancer chemotherapy, OC144-093, by human liver microsomes. Eur J Drug Metab Pharmacokinet 26:273
12. Haddad R, Colevas AD, Tishler R, Busse P, Goguen L, Sullivan C, Norris CM, Lake-Willcutt B, Case MA, Costello R, Posner M (2003) Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous carcinoma of the head and neck: the Dana Farber Cancer Institute experience. Cancer 97:412
13. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlations of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97:3473
14. Kafka A, Sauer G, Jaeger C, Grundmann R, Kreienberg R, Zeillinge R, Dreissler H (2003) Polymorphisms C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol 22:1117
15. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG, Wilkinson GR (2001) Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70:189
16. Koukourakis MI, Bahlitzanakis N, Froudarakis M, Giatromanolaki A, Georgoulias V, Koumiotaki S, Christodoulou M, Kyrias G, Skarlatos J, Kostantelos J, Beroukas J (1999) Concurrent conventionally fractionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small-cell lung carcinoma. Br J Cancer 80:1792
17. Kruijtzer CMF, Malingré MM, Schornagel JH, Smit WM, Richel DJ, ten Bokkel Huinink WW, Rosing H, de Gast GC, Schot M, Mackay M, Beijnen JH, Schellens JHM (2002) Activity and toxicity of weekly oral docetaxel plus cyclosporin A in patients with metastatic breast cancer. Results of a phase II study. Thesis University Utrecht Clinical evaluation of novel strategies for oral chemotherapy
18. Liu G, Franssen E, Fitch MI, Warner E (1997) Patients preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15:110
19. Malingré MM, Richel DJ, Beijnen JH, Rosing H, Koopman FJ, ten Bokkel Huinink WW, Schot ME, Schellens JHM (2001) Coadministration of cyclosporine strongly enhanced the oral bioavailability of docetaxel. J Clin Oncol 19:1160
20. Newman MJ, Rodarte JC, Benbatoul KD, Romano SJ, Zhang C, Krane S, Moran EJ, Uyeda RT, Dixon R, Guns ES, Mayer LD (2000) Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Res 60:2964
21. Rosing H, Lustig V, Koopman FJ, ten Bokkel Huinink WW, Beijnen JH (1997) Bio-analysis of docetaxel and hydroxylated metabolites in human plasma by high-performance liquid chromatography and automated solid-phase extraction. J Chromatogr B 696:89
22. Rosing H, Lustig V, Van Warmerdam LJC, Huizing MT, ten Bokkel Huinink WW, Schellens JH, Rodenhuis S, Bult A, Beijnen JH (2000) Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion. Cancer Chemother Pharmacol 45:213
23. Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, Sakai T, Morita Y, Tamura T, Aoyama N, Hirai M, Kasuga MK, Okumura K (2001) MDR genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 18:1400
24. Schellens JH, Malingré MM, Kruijtzer CM, Bardelmeijer HA, van Tellingen O, Schinkel AH, Beijnen JH (2000) Modulation of oral bioavailability of anticancer drugs: from mouse to man. Eur J Pharm Sci 12:103
25. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willlingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 84:7735
26. Thomas H, Coley HM (2003) Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control 10:159
27. Wils P, Phung-Ba V, Warnery A, Lechardeur D, Raeissi S, Hidalgo IJ, Scherman D (1994) Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem Pharmacol 48:1528